{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:48:29Z","timestamp":1792165709805,"version":"4.4.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>To evaluate the outcomes of robotic retroperitoneal lymph node dissection (R-RPLND) for post-chemotherapy residual retroperitoneal masses in patients with testicular non-seminomatous germ cell tumours. Open retroperitoneal lymph node dissection (O-RPLND) is associated with long skin incisions, increased post-operative pain and prolonged recovery. R-RPLND is a minimally invasive alternative, offering improved visualisation and precision, particularly in proximity to major vessels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>A retrospective analysis of patients who underwent R-RPLND at our centre between January 2023 and January 2026 was conducted. Patient selection was based on imaging and technical feasibility following informed consent. Procedures were performed by a high-volume robotic surgeon using the da Vinci Xi system. Demographic, perioperative and pathological outcomes were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Ten patients underwent R-RPLND during the study period. The median age was 27 years. Embryonal carcinoma was the predominant histology on orchiectomy (70%). Sixty percent of patients had clinical N3 disease. Post-chemotherapy serum tumour markers normalised in all but two patients who required second-line chemotherapy. The mean residual nodal mass size was 4 \u00b1 1.58 cm. The median console time and estimated blood loss were 240 min (interquartile range [IQR]: 240\u2013310) and 220 ml (IQR: 90\u2013300), respectively. Three patients required open conversion. Histopathology revealed necrosis in 40%, teratoma in 40% and viable tumour in 20% of the cases. There were no recurrences at a median follow-up of 20 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>R-RPLND is a safe and feasible alternative to O-RPLND in carefully selected patients. Optimal outcomes depend on meticulous pre-operative planning, patient selection and surgical expertise.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jmas.jmas_317_26","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:00:40Z","timestamp":1792162840000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Robotic retroperitoneal lymph node dissection for post-chemotherapy nodal mass in testicular non-seminomatous germ cell tumours: Initial experience, insights into patient selection and point of technique"],"prefix":"10.4103","author":[{"given":"Kevin","family":"Arulraj","sequence":"first","affiliation":[{"name":"Department of Urology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Panaiyadiyan","sequence":"additional","affiliation":[{"name":"Department of Urology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brusabhanu","family":"Nayak","sequence":"additional","affiliation":[{"name":"Department of Urology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"R1-20261016","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.eururo.2023.04.010","article-title":"European Association of Urology guidelines on testicular cancer: 2023 update","volume":"84","author":"Patrikidou","year":"2023","journal-title":"Eur Urol"},{"key":"R2-20261016","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1464-410X.2009.08888.x","article-title":"Morbidity of open retroperitoneal lymph node dissection for testicular cancer: Contemporary perioperative data","volume":"105","author":"Williams","year":"2010","journal-title":"BJU Int"},{"key":"R3-20261016","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0090-4295(03)00324-8","article-title":"Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: A long-term update","volume":"62","author":"Bhayani","year":"2003","journal-title":"Urology"},{"key":"R4-20261016","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.urology.2005.07.022","article-title":"Robotic-assisted laparoscopic retroperitoneal lymph node dissection","volume":"67","author":"Davol","year":"2006","journal-title":"Urology"},{"key":"R5-20261016","doi-asserted-by":"crossref","first-page":"949","DOI":"10.21037\/tau.2020.02.09","article-title":"Primary and post-chemotherapy robotic retroperitoneal lymph node dissection for testicular cancer: A review","volume":"9","author":"Ray","year":"2020","journal-title":"Transl Androl Urol"},{"key":"R6-20261016","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.21037\/tau.2019.12.36","article-title":"Robot-assisted laparoscopic retroperitoneal lymph node dissection: A minimally invasive surgical approach for testicular cancer","volume":"9","author":"Mittakanti","year":"2020","journal-title":"Transl Androl Urol"},{"key":"R7-20261016","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/bju.15986","article-title":"Robot-assisted retroperitoneal lymph node dissection: A systematic review of perioperative outcomes","volume":"132","author":"Garg","year":"2023","journal-title":"BJU Int"},{"key":"R8-20261016","doi-asserted-by":"crossref","first-page":"111.e7","DOI":"10.1016\/j.urolonc.2022.11.006","article-title":"Robotic post-chemotherapy retroperitoneal lymph node dissection for testicular cancer: A multicenter collaborative study","volume":"41","author":"Ghoreifi","year":"2023","journal-title":"Urol Oncol"},{"key":"R9-20261016","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ajur.2025.03.011","article-title":"Robot-assisted post-chemotherapy retroperitoneal lymph node dissection for metastatic non-seminomatous germ cell tumors using two distinct surgical approaches: A tertiary care experience","volume":"13","author":"Li","year":"2025","journal-title":"Asian J Urol"},{"key":"R10-20261016","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/bco2.149","article-title":"Robotic retroperitoneal lymph node dissection for testicular cancer at a national referral centre","volume":"3","author":"Grenabo Bergdahl","year":"2022","journal-title":"BJUI Compass"},{"key":"R11-20261016","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ajur.2020.09.002","article-title":"Robot-assisted retroperitoneal lymphadenectomy: The state of art","volume":"8","author":"Rodrigues","year":"2021","journal-title":"Asian J Urol"},{"key":"R12-20261016","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.3390\/cancers17091476","article-title":"Robotic retroperitoneal lymph node dissection for testicular cancer-first experience and learning curve of a single surgeon","volume":"17","author":"Angerer","year":"2025","journal-title":"Cancers (Basel)"},{"key":"R13-20261016","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/jmas.jmas_141_22","article-title":"Robot-assisted retroperitoneal lymph node dissection for post-chemotherapy residual mass in testicular cancer: Long-term experience from a tertiary care centre","volume":"19","author":"Vasudeo","year":"2023","journal-title":"J Minim Access Surg"}],"container-title":["Journal of Minimal Access Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jmas.jmas_317_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:00:43Z","timestamp":1792162843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jmas.jmas_317_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":13,"URL":"https:\/\/doi.org\/10.4103\/jmas.jmas_317_26","relation":{},"ISSN":["0972-9941","1998-3921"],"issn-type":[{"value":"0972-9941","type":"print"},{"value":"1998-3921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"2026-05-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}